Rare Disease Drug Market Size, COVID-19 Impact Analysis By Regional Outlook (Europe, North America, Asia Pacific, Middle East & Africa And South America), Growth Potential, Price Trends, Competitive Market Share & Forecast 2023 - 2028 (Updated Version Available)
Rare Disease Drug Market Size, COVID-19 Impact Analysis By Regional Outlook (Europe, North America, Asia Pacific, Middle East & Africa And South America), Growth Potential, Price Trends, Competitive Market Share & Forecast 2023 - 2028 (Updated Version Available)
ID : MRI21665 | Date : Jan, 2021 | Pages :
180 | Region : Global |
Publisher : RI
The Rare Disease Drug market report provides a detailed analysis of global market size, value chain optimization, segmentation market growth, market share, competitive Landscape, regional and country-level market size, sales analysis, impact of domestic and global market players, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The global Rare Disease Drug market size is expected to gain market growth in the forecast period of 2020 to 2028, with a CAGR of xx%% in the forecast period of 2020 to 2028 and will expected to reach USD xx million by 2028, from USD xx million in 2020.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
>1‰
0.65‰~1‰
<0.1‰
By Application
Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Others
Competitive Landscape and Rare Disease Drug Market Share Analysis
Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):
Novartis AG
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi S.A.
Alexion Pharmaceuticals, Inc.
Eli Lilly and Company
Novo Nordisk A/S
AstraZeneca
Eisai Co., Ltd.
Daiichi Sankyo Company Limited
Bayer AG
GlaxoSmithKline
Merck & Co., Inc.
Johnson & Johnson
Biogen, Inc.
Shire
Amgen, Inc.
Deciphera
Atara Biotherapeutics
ProQR
Rare Disease Drug competitive landscape provides details by vendors, including company overview, company total revenue (financial), market potential, global presence, Rare Disease Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Rare Disease Drug sales, revenue and market share for each player covered in this report.
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Rare Disease Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Rare Disease Drug markets. For the historical and forecast period 2015 to 2028, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Rare Disease Drug market.
Region Coverage (Regional Production, Demand & Forecast by Countries etc.): North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Rare Disease Drug market for the forecast period 2020 - 2028?
• What are the driving forces in the Rare Disease Drug market for the forecast period 2020 - 2028?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Rare Disease Drug industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?
Table of Contents
1 Study Coverage
1.1 Rare Disease Drug Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Rare Disease Drug Market Size Growth Rate by Product
1.4.2 >1‰
1.4.3 0.65‰~1‰
1.4.4 <0.1‰
1.5 Market by End User
1.5.1 Global Rare Disease Drug Market Size Growth Rate by End User
1.5.2 Hospital Pharmacies
1.5.3 Speciality Pharmacies
1.5.4 Retail pharmacies
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Rare Disease Drug Market Size
2.1.1 Global Rare Disease Drug Revenue 2015-2028
2.1.2 Global Rare Disease Drug Sales 2015-2028
2.2 Rare Disease Drug Growth Rate by Regions
2.2.1 Global Rare Disease Drug Sales by Regions
2.2.2 Global Rare Disease Drug Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Rare Disease Drug Sales by Manufacturers
3.1.1 Rare Disease Drug Sales by Manufacturers
3.1.2 Rare Disease Drug Sales Market Share by Manufacturers
3.1.3 Global Rare Disease Drug Market Concentration Ratio (CR5 and HHI)
3.2 Rare Disease Drug Revenue by Manufacturers
3.2.1 Rare Disease Drug Revenue by Manufacturers (2015-2020)
3.2.2 Rare Disease Drug Revenue Share by Manufacturers (2015-2020)
3.3 Rare Disease Drug Price by Manufacturers
3.4 Rare Disease Drug Manufacturing Base Distribution, Product Types
3.4.1 Rare Disease Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Rare Disease Drug Product Type
3.4.3 Date of International Manufacturers Enter into Rare Disease Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Rare Disease Drug Sales by Product
4.2 Global Rare Disease Drug Revenue by Product
4.3 Rare Disease Drug Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Rare Disease Drug Breakdown Data by End User
6 North America
6.1 North America Rare Disease Drug by Countries
6.1.1 North America Rare Disease Drug Sales by Countries
6.1.2 North America Rare Disease Drug Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Rare Disease Drug by Product
6.3 North America Rare Disease Drug by End User
7 Europe
7.1 Europe Rare Disease Drug by Countries
7.1.1 Europe Rare Disease Drug Sales by Countries
7.1.2 Europe Rare Disease Drug Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Rare Disease Drug by Product
7.3 Europe Rare Disease Drug by End User
8 Asia Pacific
8.1 Asia Pacific Rare Disease Drug by Countries
8.1.1 Asia Pacific Rare Disease Drug Sales by Countries
8.1.2 Asia Pacific Rare Disease Drug Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Rare Disease Drug by Product
8.3 Asia Pacific Rare Disease Drug by End User
9 Central & South America
9.1 Central & South America Rare Disease Drug by Countries
9.1.1 Central & South America Rare Disease Drug Sales by Countries
9.1.2 Central & South America Rare Disease Drug Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Rare Disease Drug by Product
9.3 Central & South America Rare Disease Drug by End User
10 Middle East and Africa
10.1 Middle East and Africa Rare Disease Drug by Countries
10.1.1 Middle East and Africa Rare Disease Drug Sales by Countries
10.1.2 Middle East and Africa Rare Disease Drug Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Rare Disease Drug by Product
10.3 Middle East and Africa Rare Disease Drug by End User
11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Details
11.1.2 Company Business Overview
11.1.3 Novartis AG Rare Disease Drug Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Rare Disease Drug Products Offered
11.1.5 Novartis AG Recent Development
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Details
11.2.2 Company Business Overview
11.2.3 Bristol-Myers Squibb Company Rare Disease Drug Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bristol-Myers Squibb Company Rare Disease Drug Products Offered
11.2.5 Bristol-Myers Squibb Company Recent Development
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Details
11.3.2 Company Business Overview
11.3.3 Celgene Corporation Rare Disease Drug Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Celgene Corporation Rare Disease Drug Products Offered
11.3.5 Celgene Corporation Recent Development
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 F. Hoffmann-La Roche Ltd. Company Details
11.4.2 Company Business Overview
11.4.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales, Revenue and Gross Margin (2015-2020)
11.4.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Products Offered
11.4.5 F. Hoffmann-La Roche Ltd. Recent Development
11.5 Pfizer, Inc.
11.5.1 Pfizer, Inc. Company Details
11.5.2 Company Business Overview
11.5.3 Pfizer, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer, Inc. Rare Disease Drug Products Offered
11.5.5 Pfizer, Inc. Recent Development
11.6 Sanofi S.A.
11.6.1 Sanofi S.A. Company Details
11.6.2 Company Business Overview
11.6.3 Sanofi S.A. Rare Disease Drug Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Sanofi S.A. Rare Disease Drug Products Offered
11.6.5 Sanofi S.A. Recent Development
11.7 Alexion Pharmaceuticals, Inc.
11.7.1 Alexion Pharmaceuticals, Inc. Company Details
11.7.2 Company Business Overview
11.7.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Alexion Pharmaceuticals, Inc. Rare Disease Drug Products Offered
11.7.5 Alexion Pharmaceuticals, Inc. Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Company Business Overview
11.8.3 Eli Lilly and Company Rare Disease Drug Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Eli Lilly and Company Rare Disease Drug Products Offered
11.8.5 Eli Lilly and Company Recent Development
11.9 Novo Nordisk A/S
11.9.1 Novo Nordisk A/S Company Details
11.9.2 Company Business Overview
11.9.3 Novo Nordisk A/S Rare Disease Drug Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Novo Nordisk A/S Rare Disease Drug Products Offered
11.9.5 Novo Nordisk A/S Recent Development
11.10 AstraZeneca
11.10.1 AstraZeneca Company Details
11.10.2 Company Business Overview
11.10.3 AstraZeneca Rare Disease Drug Sales, Revenue and Gross Margin (2015-2020)
11.10.4 AstraZeneca Rare Disease Drug Products Offered
11.10.5 AstraZeneca Recent Development
11.11 Eisai Co., Ltd.
11.12 Daiichi Sankyo Company Limited
11.13 Bayer AG
11.14 GlaxoSmithKline
11.15 Merck & Co., Inc.
11.16 Johnson & Johnson
11.17 Biogen, Inc.
11.18 Shire
11.19 Amgen, Inc.
11.20 Deciphera
11.21 Atara Biotherapeutics
11.22 ProQR
12 Future Forecast
12.1 Rare Disease Drug Market Forecast by Regions
12.1.1 Global Rare Disease Drug Sales Forecast by Regions 2021-2028
12.1.2 Global Rare Disease Drug Revenue Forecast by Regions 2021-2028
12.2 Rare Disease Drug Market Forecast by Product
12.2.1 Global Rare Disease Drug Sales Forecast by Product 2021-2028
12.2.2 Global Rare Disease Drug Revenue Forecast by Product 2021-2028
12.3 Rare Disease Drug Market Forecast by End User
12.4 North America Rare Disease Drug Forecast
12.5 Europe Rare Disease Drug Forecast
12.6 Asia Pacific Rare Disease Drug Forecast
12.7 Central & South America Rare Disease Drug Forecast
12.8 Middle East and Africa Rare Disease Drug Forecast
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Rare Disease Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Research Methodology
The Market Reports Insights offers numerous solutions and its full addition in the research methods to be skilled at each step. We use wide-ranging resources to produce the best outcome for our customers. The achievement of a research development is completely reliant on the research methods implemented by the company. We always faithful to our clients to find opportunities by examining the global market and offering economic insights.
Market Reports Insights are proud of our widespread coverage that encompasses the understanding of numerous major industry domains. Company offers consistency in our research report, we also offers on the part of the analysis of forecast across a range of coverage geographies and coverage. The research teams carry out primary and secondary research to carry out and design the data collection methods.
The Company's Research Process Has the Following Advantages:
Information Procurement
The step comprises the procurement of market-related information or data via different methodologies & sources.
Information Investigation
This step comprises the mapping and investigation of all the information procured from the earlier step. It also includes the analysis of data differences observed across numerous data sources.
Highly Authentic Source
We offer highly authentic information from numerous sources. To fulfills the client’s requirement.
Market Formulation
This step entails the placement of data points at suitable market spaces in an effort to assume possible conclusions. Analyst viewpoint and subject matter specialist based examining the form of market sizing also plays an essential role in this step.
Validation & Publishing of Information
Validation is a significant step in the procedure. Validation via an intricately designed procedure assists us to conclude data-points to be used for final calculations.
Well researched, expertise analysts, well organized, concrete and current topics delivered in time.
- President and CEO
Very helpful to understand overview of business status, by customers, categories, timeless, and regions. Able to build the future business strategy on the basis of research report. Validated and researched information of reports.
- Senior Manager, Product Development
We are very thankful to (company name) for detailed research report delivering in short period of time. Good market research Company really commendable.
- Senior Manager, Product Development
Excellent services, unique and very professional. The effort taken to make sure relevance to our requirements ensured the best possible outcome.